Table A1.
Baseline characteristics of patients with localized non-small cell lung cancer who were treated with stereotactic body radiation therapy and divided into three groups: normal vs. abnormal G-8 scores, high vs. intermediate vs. low G-8 scores, and fit vs. vulnerable vs. frail G-8+HGST scores.
| Patient Characteristics | G-8, 2 Groups | G-8, 3 Groups 1 | G-8 + HGST 2 | |||||
|---|---|---|---|---|---|---|---|---|
| Normal | Abnormal | High | Intermediate | Low | Fit | Vulnerable | Frail | |
| Sex | ||||||||
| Female | 4 (31%) | 21 (64%) | 4 (31%) | 17 (68%) | 4 (50%) | 6 (60%) | 10 (36%) | 5 (62.5%) |
| Male | 9 (69%) | 12 (36%) | 9 (69%) | 8 (32%) | 4 (50%) | 4 (40%) | 18 (64%) | 3 (37.5%) |
| Age | ||||||||
| Median (range) | 72 (52–79) | 72 (56–87) | 72 (52–79) | 72 (56–87) | 71 (57–83) | 72 (52–79) | 73 (58–87) | 71 (57–80) |
| ≥70 years (%) | 9 (69%) | 25 (74%) | 9 (69%) | 19 (76%) | 5 (63%) | 6 (60%) | 21 (75%) | 6 (75%) |
| Reason of SBRT referral | ||||||||
| Unfit for surgery 3 | 13 (100%) | 29 (88%) | 13 (100%) | 22 (88%) | 7 (88%) | 10 (100%) | 26 (93%) | 6 (75%) |
| Declined surgery | 0 (0%) | 4 (12%) | 0 (0%) | 3 (12%) | 1 (12%) | 0 (0%) | 2 (7%) | 2 (25%) |
| Lung cancer stage | ||||||||
| 1A | 8 (61%) | 22 (68%) | 8 (61%) | 16 (64%) | 6 (75%) | 6 (60%) | 18 (64%) | 6 (75%) |
| 1B | 4 (31%) | 11 (32%) | 4 (31%) | 9 (36%) | 2 (25%) | 3 (30%) | 10 (36%) | 2 (25%) |
| Synchronous NSCLC | 1 (8%) | 0 (0%) | 1 (8%) | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 0 (0%) |
| Histology | ||||||||
| Adeno | 7 (54%) | 16 (47%) | 7 (54%) | 11 (44%) | 5 (63%) | 7 (70%) | 12 (43%) | 4 (50%) |
| Non-adeno | 6 (46%) | 18 (53%) | 6 (46%) | 14 (56%) | 3 (37%) | 3 (30%) | 16 (57%) | 4 (50%) |
| Prescribed radiation dose | ||||||||
| 45Gy/3F(BED 112Gy) | 2 (15%) | 2 (6%) | 2 (15%) | 2 (8%) | 0 (0%) | 2 (20%) | 2 (7%) | 0 (0%) |
| 66Gy/3F (BED 211Gy) | 11 (85%) | 31 (94%) | 11 (85%) | 23 (92%) | 8 (100%) | 8 (80%) | 26 (93%) | 8 (100%) |
| ECOG Performance status | ||||||||
| 0–1 | 11 (85%) | 17 (50%) | 11 (85%) | 14 (56%) | 3 (37%) | 9 (90%) | 16 (57%) | 3 (37%) |
| ≥2 | 2 (15%) | 17 (50%) | 2 (15%) | 11 (44%) | 5 (63%) | 1 (10%) | 12 (43%) | 5 (65% |
| CCI | ||||||||
| 0–1 | 7 (54%) | 13 (38%) | 7 (54%) | 9 (36%) | 3 (37%) | 6 (60%) | 10 (36%) | 3 (37%) |
| 2–3 | 4 (31%) | 17 (50%) | 4 (31%) | 13 (52%) | 4 (50%) | 2 (20%) | 14 (50%) | 5 (63%) |
| >3 | 2 (15%) | 4 (12%) | 2 (15%) | 3 (12%) | 1 (13%) | 2 (20%) | 4 (14%) | 0 (0%) |
| Barthel 20 | ||||||||
| Normal (20–19) | 10 (77%) | 22 (65%) | 10 (77%) | 19 (79%) | 3 (37%) | 8 (80%) | 20 (71%) | 4 (50%) |
| Disability (≤18) | 3 (23%) | 12 (35%) | 3 (23%) | 6 (24%) | 5 (63%) | 2 (20%) | 8 (29%) | 4 (50%) |
| G-8 total | ||||||||
| Normal (>14) | 13 (100%) | 0 (0%) | 13 (100%) | 0 (0%) | 0 (0%) | 10 (100%) | 3 (11%) | 0 (0%) |
| Abnormal (≤14) | 0 (0%) | 43 (100%) | 0 (0%) | 25 (100%) | 8 (100%) | 0 (0%) | 25 (89%) | 8 (100%) |
| CST | ||||||||
| Normal (≥10) | 1 (25%) | 2 (22%) | 1 (25%) | 1 (12%) | 1 (100%) | 0 (0%) | 3 (27%) | 0 (0%) |
| Abnormal (<10) | 3 (75%) | 7 (78%) | 3 (75%) | 7 (88%) | 0 (0%) | 2 (100%) | 8 (73%) | 0 (0%) |
| HGST | ||||||||
| Normal (♂ ≥ 21 kg/♀ ≥ 15 kg) | 10 (77%) | 25 (76%) | 10 (77%) | 20 (80%) | 5 (63%) | 10 (100%) | 25 (89%) | 0 (0%) |
| Abnormal (♂ < 21 kg/♀ < 15 kg) | 3 (23%) | 8 (24%) | 3 (23%) | 5 (20%) | 3 (37%) | 0 (0%) | 3 (11%) | 8 (100%) |
| CGA 4 | ||||||||
| Yes | 6 (46%) | 19 (56%) | 6 (46%) | 15 (60%) | 3 (37%) | 6 (60%) | 12 (43%) | 4 (50%) |
| No | 7 (54%) | 15 (44%) | 7 (54%) | 10 (40%) | 5 (63%) | 4 (40%) | 16 (57%) | 4 (50%) |
ECOG Performance Status—Eastern Cooperative Oncology Group’s definition of performance status, G-8—Geriatric 8 screening tool, CST—Chair-stand test, HGST—Hand-grip strength test, ♂—male, ♀—female, G-8 + HGST—Combination of Geriatric 8 and hand-grip strength test, CGA—Comprehensive Geriatric Assessment. 1 High G-8 score (>14), Intermediate G-8 score (11–14), and Low G-8 score (<11). 2 Geriatric 8 screening tool and hand-grip strength test combination. Hand-grip strength was measured using a Smedley Dynamometer. Fit (normal G-8 and normal HGST), Vulnerable (abnormal G-8 or abnormal HGST), and Frail (abnormal G-8 and abnormal HGST). 3 Unfit for surgery encompasses patients considered medically inoperable or best served with SBRT. 4 Patients were randomized 1:1 to receive CGA or not upon inclusion in the previous randomized study. A statistically significant difference was found in ECOG-PS scores between patients with normal vs. abnormal G-8 scores (p = 0.05). Otherwise, no statistically significant differences were observed between the two G-8 groups, the three G-8 groups, or the fit, vulnerable, or frail combination groups.